MedTrace Logo

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

NCT04427774 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-07-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

Surufatinib plus Sintilimab

Surufatinib will be given orally. Sintilimab will be given intravenously

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2021-02-08
Completion
2021-04-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04427774 on ClinicalTrials.gov